MAR 10, 2015 9:00 AM PDT

Newly Updated Guidelines for the Diagnosis of Multiple Myeloma

Sponsored by: Binding Site, Binding Site
Speaker
  • Professor of Medicine & Chief of Multiple Service at Memorial Sloan-Kettering in New York City
    Biography
      Dr. Landgren is Professor of Medicine and Chief Attending Physician of the Myeloma Service at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, NY. Dr. Landgren is one of the world leaders in the field of early treatment strategies and molecular- and cell-based monitoring of minimal residual disease (MRD) detection in multiple myeloma and its precursor states. He leads a translational research program at MSKCC designed to discover new treatment paradigms integrating modern therapy and novel MRD assays. Dr. Landgren has designed and led the definitive study showing that all multiple myeloma patients are preceded by a precursor stage. As part of his ongoing research program, he is studying molecular mechanisms underlying the trajectory from precursor to full-blown multiple myeloma with the goal to develop of treatment strategies aiming to delay, prevent, and ultimately define a cure for multiple myeloma.

      Dr. Landgren has published over 250 peer-reviewed publications and he is a frequently invited speaker at national and international hematology conferences. He serves on several research committees and editorial boards for scientific journals.

    Abstract
    DATE: Tuesday, March 10, 2015
    TIME: 09:00 PST, 11:00 CST, 12:00 EST, 16:00 GMT


    The International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple myeloma.

    The updated criteria, published in The Lancet Oncology represent a significant change in how Multiple Myeloma is diagnosed and the stage at which patients should be treated.

    Join us on March 10th on a webinar covering these updated criteria for Myeloma and related plasma cell disorders and the importance of biomarkers in Early Stage Disease.
    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
    Following this presentation the listener will:
    • Understand the history and traditional tools used to diagnose Myeloma
    • Gain an appreciation for the evolution of Myeloma diagnosis and biomarkers of the disease
    • Be able to understand how to apply the new diagnostic guidelines to the diagnosis and treatment of Myeloma.

    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 31, 2020 9:00 AM PDT
    C.E. CREDITS
    MAR 31, 2020 9:00 AM PDT
    DATE: March 31, 2020 TIME: 9:00am PT, 12:00pm ET HER2-positive breast cancer is a type of breast cancer caused by over-expression of a protein called human epidermal growth factor receptor 2...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    Loading Comments...
    Show Resources
    Attendees
    • See more